Cornerstone Therapeutics Inc: (NASD: CRTX)
$9.04
0.10 (1.12%)
Volume 86,254
May 14 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 8.87 - 9.04 |
| 52wk Low - High | 3.10 - 9.04 |
| Previous Close | 8.94 |
| Avg. Volume | 84,148 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 238.87 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | -0.68 |
| PE (Forward) | 13.34 |
| Current Year Est. | 0.67 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
79 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 13.34 |
| PEG Ratio | NA |
| Current Year Est. | 0.67 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | 0.67 |
| Expected Earnings Growth | NA |
Company Description
CORNERSTONE THERAPEUTICS is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a deep late-stage clinical pipeline with six regulatory approval submissions expected between 2009 and 2010. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CORNERSTONE THR | CRTX | 8.94 | |
|
| AETERNA ZENTARS | AEZS | 1.87 | |
|
| ANIKA THERAPEUT | ANIK | 13.90 | |
|
| GENTIUM SPA-ADR | GENT | 8.31 | |
|
| NOVELOS THERAPT | NVLT | 0.44 | |
|
| AASTROM BIOSCI | ASTM | 0.60 | |
|
| ACHILLION PHARM | ACHN | 7.25 | |
|
| AFFYMAX INC | AFFY | 1.31 | |
|
| ALEXION PHARMA | ALXN | 104.86 | |
|
| ALKERMES INC | ALKS | 31.47 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Zacks #5 Rank Additions for Thursday
May 09, 2013
Zacks #5 Rank Additions for Monday
May 06, 2013
Bad News for Cornerstone
Sep 20, 2012
Cornerstone Therapeutics, Inc. Enters Oversold Territory
Sep 10, 2012
Zacks #1 Rank Additions for Thursday
Aug 30, 2012
Report Not Available
Financials
| EPS TTM | 0.67 |
| Sales | 116 |
| Net Income | -8 |
| Price/Earnings | 13.34 |
| Price/Book | 1.42 |
| Price/Cash Flow | 7.14 |
| Price/Sales | 1.81 |
News
Cornerstone Therapeutics Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 10, 2013
Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights toPERTZYE(R) (pancrelipase) for Treatment of Exocrine PancreaticInsufficiency in Patients With Cystic Fibrosis - Marketwire
May 9, 2013
Cornerstone Therapeutics Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 9, 2013
Cornerstone Therapeutics Makes a Move: Up 3.7% - Financial News Network Online - Market Movers
May 9, 2013
Cornerstone Therapeutics Reports First Quarter 2013 Financial Results - Marketwire
May 9, 2013
Cornerstone Therapeutics Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 8, 2013
Cornerstone Therapeutics Up 27.8% Since SmarTrend Uptrend Call (CRTX) - Comtex Smartrend(R)
May 8, 2013
REMINDER: Cornerstone Therapeutics to Host First Quarter 2013Conference Call - Marketwire
May 8, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 14.00 |
| Industry Rank by ABR | 79 out of 265 |
| Rank in Industry | 5 out of 155 |
